NORCROSS, Ga., March 19 /PRNewswire-FirstCall/ -- Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced that on Friday, March 16, 2007, the company submitted the 510(k) premarket notification submission for its Galileo(R) Echo(TM) instrument to the U.S. Food and Drug Administration.
Commenting on the submission Dr. Gioacchino De Chirico, President and CEO stated "We are very pleased to have filed this submission and look forward to selling the instrument in the United States upon receiving FDA clearance."
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments.
For more information on Immucor, please visit our website at http://www.immucor.com.
Statements contained in this press release that are not statements of historical fact are "forward-looking statements" as that term is defined under federal securities laws. Investors are cautioned not to place undue reliance on any forward-looking statements. In particular, our ability to sell the Galileo Echo in the United States is dependent on FDA clearance, and there is no guarantee whether or when the FDA will give that clearance. Further risks are detailed in the Company's filings with the Securities and Exchange Commission. Immucor assumes no obligation to update any forward-looking statements.
Immucor, Inc.CONTACT: Patrick Waddy of Immucor, Inc., +1-770-441-2051
Web site: http://www.immucor.com/
